Medication adherence rates in U.S. unaffected by interventions according to new article led by FDA and National Forum for Heart Disease & Stroke Prevention
People not taking prescribed medications is a major reason that heart disease and stroke persist as the leading cause of death, according to a new Journal of the American College of Cardiology report. The authors found that no single intervention has substantially altered medication adherence rates in the United States, and called for collaborative research to improve medication adherence among cardiovascular disease patients.
FDA and HHS issue new voluntarily guidelines to reduce sodium in processed and commercially prepared food.
The National Forum for Heart Disease & Stroke Prevention congratulates Dr. Robert Califf on his confirmation as F.D.A. Commissioner.
As part of the largest scale World Heart Day initiative in the organization's history, the National Forum for Heart Disease & Stroke Prevention is helping Americans take steps to reduce high cholesterol and other heart disease and stroke risk factors.
The National Forum is pleased that the U.S. Food and Drug Administration (FDA) approved Repatha™ (evolocumab), the second PCSK9 inhibitor to enter the market this year.
Praluent® (alirocumab) Injection today to help reduce low density lipoprotein (LDL-C) or “bad” cholesterol in certain people whose high LDL-C levels put them at risk of heart attack or stroke.
As an organization dedicated to improving cardiovascular health, the National Forum is excited that the FDA approved Entresto ™ (sacubitril/valsartan) as it has the potential to reduce heart failure mortality in the U.S.
The National Forum is encouraged by the efficacy data from recent PCSK9 inhibitor trials.
National Forum convened a panel of experts in the field of cardiology on Friday, March 13, 2015 to launch its cholesterol initiative in San Diego, Calif.